JRCT ID: jRCT2031220098
Registered date:28/05/2022
A Phase 3 study of MK-7684A in combination with chemotherapy in metastatic NSCLC
Basic Information
Recruitment status | Not Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Non-Small Cell Lung Cancer |
Date of first enrollment | 18/05/2022 |
Target sample size | 46 |
Countries of recruitment | USA,Japan,Mexico,Japan,Colombia,Japan,Chile,Japan,Brazil,Japan,Argentina,Japan,Austria,Japan,Germany,Japan,Israel,Japan,Poland,Japan,Russia,Japan,Spain,Japan,Turkey,Japan,Ukraine,Japan,France,Japan,UK,Japan,South Korea,Japan,China,Japan,Taiwan,Japan,Thailand,Japan |
Study type | Interventional |
Intervention(s) | Participants will receive 4 cycles of MK-7684A (coformulation of MK-7684 200mg and MK-3475 200mg) or MK-3475 200mg Q3W in combination with chemotherapy followed by up to 31 cycles of MK-7684A or MK-3475 (including pemetrexed for participants with nonsquamous NSCLC) Q3W. Platinum Doublet Chemotherapy: - Participants with squamous NSCLC will receive 4 cycles of carboplatin with taxane (paclitaxel/nab-paclitaxel). - Participants with nonsquamous NSCLC will receive 4 cycles of pemetrexed with platinum (cisplatin/carboplatin) followed by pemetrexed maintenance until progression, intolerable AE, or discontinuation by decision of participant or physician. |
Outcome(s)
Primary Outcome | - Overall Survival (OS) |
---|---|
Secondary Outcome | - Progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR) - Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR - Mean change from baseline in global health status/quality of life (QoL), physical functioning, dyspnea, cough, and chest pain - Time to True Deterioration (TTD) in global health status/QoL, physical functioning, dyspnea, cough, and chest pain - Safety and tolerability - Duration of Response (DOR) per RECIST 1.1 as assessed by BICR |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | - A histologically or cytologically confirmed diagnosis of Stage IV squamous or non-squamous NSCLC. - Has not received prior systemic treatment for metastatic NSCLC. - Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as determined by the local site assessment. - Has a life expectancy of at least 3 months. - Males: Use contraception unless confirmed to be azoospermic; Females: Women of childbearing potential use highly effective contraceptive method. |
Exclude criteria | - Known additional malignancy that is progressing or has required active treatment within the past 3 years. - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. - Severe hypersensitivity to vibostolimab, pembrolizumab, chemotherapy components, and/or any of its excipients. - Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication. - Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. - History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. - Has an active infection requiring systemic therapy. - Has a known history of human immunodeficiency virus (HIV), Hepatitis B or/and Hepatitis C virus. - Received prior systemic anticancer therapy for metastatic disease. - Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. - History of allogenic tissue/solid organ transplant. - Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose =< 1.3 g/day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). - Is unable or unwilling to take folic acid or vitamin B12 supplementation. - Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. |
Related Information
Primary Sponsor | Nohata Nijiro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT05226598 |
Contact
Public contact | |
Name | inquiry mailbox MSDJRCT |
Address | KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan Tokyo Japan 102-8667 |
Telephone | +81-3-6272-1957 |
msdjrct@merck.com | |
Affiliation | MSD K.K. |
Scientific contact | |
Name | Nijiro Nohata |
Address | KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan Tokyo Japan 102-8667 |
Telephone | +81-3-6272-1957 |
msdjrct@merck.com | |
Affiliation | MSD K.K. |